OUR CURRENT OFFERINGS

Home

This new offering consists of a newly-constructed dialysis clinic leased to Fresenius Medical Care Holdings for 15-years.

MINIMUM EQUITY:
$100,000
CAP RATE:
6.07%
CASH FLOW:
6.00%

This new offering consists of a newly-constructed dialysis clinic leased to Fresenius Medical Care Holdings for 15-years. Fresenius Medical Care Holdings is a wholly-owned subsidiary of Fresenius Medical Care, a New York Stock Exchange company (ticker symbol: FMS). Fresenius is a 100-year old company and is the world's largest integrated provider of dialysis products and services. Fresenius is a "Global Fortune 500" company with a market capitalization of approximately $27 billion.
INVESTMENT HIGHLIGHTS
› 6.00% INITIAL CASH FLOW (EST)
› NEWLY-CONSTRUCTED BUILDING
› LONG-TERM LEASE (15 YEARS)
› FRESENIUS IS PUBLICLY TRADED (NYSE: FMS)
› ESCALATING RENTAL SCHEDULE
› DST STRUCTURE FOR IDEAL 1031 EXCHANGE

  MORE INFORMATION

This new offering consists of two newly-constructed dialysis clinics leased to Fresenius Medical Care Holdings for 15-years.

MINIMUM EQUITY:
$100,000
CAP RATE:
6.24%
CASH FLOW:
6.00%

This new offering consists of a two newly-constructed dialysis clinic leased to Fresenius Medical Care Holdings for 15-years. Fresenius Medical Care Holdings is a wholly-owned subsidiary of Fresenius Medical Care, a New York Stock Exchange company (ticker symbol: FMS). Fresenius is a 100-year old company and is the world's largest integrated provider of dialysis products and services. Fresenius is a "Global Fortune 500" company with a market capitalization of approximately $27 billion.
INVESTMENT HIGHLIGHTS
› 6.00% INITIAL CASH FLOW (EST)
› NEWLY-CONSTRUCTED BUILDINGS
› LONG-TERM LEASES (15 YEARS)
› FRESENIUS IS PUBLICLY TRADED (NYSE: FMS)
› ESCALATING RENTAL SCHEDULES
› DST STRUCTURE FOR IDEAL 1031 EXCHANGE

  MORE INFORMATION

This new offering consists of two newly-constructed dialysis clinics leased to DaVita Dialysis and Fresenius Medical Care for 15-years.

MINIMUM EQUITY:
$100,000
CAP RATE:
6.33%
CASH FLOW:
6.00%

This new offering consists of two newly-constructed dialysis clinics leased to Fresenius Medical Care Holdings and DaVita Healthcare Partners. Fresenius is a $27 billion worldwide company with over 105,000 employees and a network of 3,500 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. DaVita Healthcare Partners, Inc. ("DaVita") (NYSE: DVA), a Fortune 500® company, is a leading provider of kidney care in the United States and is the guarantor of the lease.
INVESTMENT HIGHLIGHTS
› 6.00% INITIAL CASH FLOW (EST)
› NEWLY-CONSTRUCTED BUILDINGS
› LONG-TERM LEASES (15 YEARS)
› FRESENIUS IS PUBLICLY TRADED (NYSE: FMS)
› DAVITA DIALYSIS IS PUBLICLY TRADED (NYSE: DVA)
› ESCALATING RENTAL SCHEDULES
› DST STRUCTURE FOR IDEAL 1031 EXCHANGE

  MORE INFORMATION

This website does not offer to sell, or a solicitation of an offer to buy, securities. Offers can only be made through the Private Placement Memorandum which contains various and important risk disclosures. This brochure does not purport to be complete and should be viewed in conjunction with the Private Placement Memorandum. An investment of this sort is speculative and involves a high degree of risk. Projections of future performance contained herein are based on specific assumptions discussed more fully in the Private Placement Memorandum and do not constitute a guaranty of future performance.

DST Interests in any of the properties displayed on this website may be sold only to "accredited investors," as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the "Securities Act"), which, for natural persons, refers to investors who meet certain minimum annual income or net worth thresholds. Offers and sales of DST interests have not and will not be registered under the Securities Act or the laws of any U.S. state or non-U.S. jurisdiction and may be offered only pursuant to an exemption from such registration. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of an investment in the DST Interests, has approved or disapproved of DST Interests or passed upon the accuracy or adequacy of this website and any supplementary materials describing the DST Interests. DST Interests are also not subject to the protections of the Investment Company Act of 1940, including the limitations on self-dealing, affiliated transactions and leverage contained therein. DST Interests are subject to legal restrictions on transfer and resale in accordance with the governing documents of the Trust and applicable securities laws, and investors may be unable to sell or transfer their DST interests. In addition, there is no public market for the DST interests and no such market is expected to develop in the future. Investing in the DST securities involves risk, and investors should be able to bear the loss of their investment.